Mezlocillinに関する基礎的検討と呼吸器感染症に対する効果

DOI Web Site

書誌事項

タイトル別名
  • LABORATORY AND CLINICAL STUDIES ON MEZLOCILLIN
  • Mezlocillin ニ カンスル キソテキ ケントウ ト コキュウキ カン

この論文をさがす

抄録

The laboratory and clinical studies on mezlocillin, a new semisynthetic penicillin, were performed with following results.<BR>1. Minimal Inhibitory Concentration (MIC) of mezlocillin against 79 strains of H. influenzae, isolated from patients with respiratory tract infections, were 0.025μg/ml (1 strain), 0.05μg/ml (25 strains), 0.1μg/ml (34 strains) and 0.2μg/ml (19 strains).<BR>The antibacterial activity of mezlocillin was from 2 to 4 times stronger than that of ampiciilin (ABPC), carbenicillin, or sulbenicillin.<BR>2. Influence of inoculum size of bacteria were studied on the β-lactamase producing, ABPC resistant strains of H. influenzae (5 strains) and H. parainfluenzae (1 strain).<BR>Mezlocillin was inactivated as well as ABPC with β-lactamase.<BR>3. Tissue concentrations in rats reached peak values at 15 minutes and they were the following order of serum, liver, kidney and lung. 2 hours later, mezlocillin was not detectable in all organs.<BR>4. Eight infections (chronic bronchitis 6, bronchoectasis 2) of 6 patients were treated with mezlocillin, which was effective in all cases.<BR>The causal organisms of the respiratory tract infections were H. influenzae in 5 cases, Streptococcus pneumoniae in 1 case and mixed infection in 2 cases.<BR>5. No side effects due to administration of this drug were noted in any of the cases.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ